share_log

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $192 Price Target

Benzinga ·  Nov 8, 2023 09:18

Wedbush analyst Andreas Argyrides reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $192 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment